PE20000441A1 - Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado - Google Patents
Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratadoInfo
- Publication number
- PE20000441A1 PE20000441A1 PE1999000356A PE00035699A PE20000441A1 PE 20000441 A1 PE20000441 A1 PE 20000441A1 PE 1999000356 A PE1999000356 A PE 1999000356A PE 00035699 A PE00035699 A PE 00035699A PE 20000441 A1 PE20000441 A1 PE 20000441A1
- Authority
- PE
- Peru
- Prior art keywords
- polymorph
- methoxyetoxy
- quinazolinamine
- mesilate
- bis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
SE REFIERE A FORMAS ANHIDRAS E HIDRATADAS DEL MESILATO DE N-(3-ETINILFENIL)-6,7-BIS-(2-METOXIETOXI)-4-QUINAZOLINAMINA, LA FORMA ANHIDRA (POLIMORFO A) SE CARACTERIZA POR SU PATRON DE DIFRACCCION DE RAYOS X. LA FORMA ANHIDRA (POLIMORFO B) SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. LA FORMA ANHIDRA (POLIMORFO C) CARACTERIZADO POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A COMPOSICIONES QUE COMPRENDEN INHIBIDORES MITOTICOS, AGENTES ALQUILANTES, ANTI-METABOLITOS, ANTIBIOTICOS INTERCALANTES, INHIBIDORES DEL FACTOR DE CRECIMIENTO, INHIBIDORES DEL CICLO CELULAR, INHIBIDORES DE LA TOPOISOMERASA, MODIFICADORES DE LA RESPUESTA BIOLOGICA, ANTI-HORMONA, ANTI-ANDROGENOS. EL COMPUESTO ES UN INHIBIDOR DE erbB DE TIROSINQUINASA ONCOGENICAS Y PROTOONCOGENICAS LAS QUE PUEDEN SER UTILES EN EL TRATAMIENTO DE UNA ALTERACION HIPERPROLIFERATIVA TAL COMO CANCER DE CEREBRO, PULMON, CELULA ESCAMOSA, VEJIGA, GASTRICO, PANCREATICO, MAMA, CABEZA, GARGANTA, RENAL, RINON, OVARICO, ESOFAGICO, GINECOLOGICO, TIROIDES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8344198P | 1998-04-29 | 1998-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20000441A1 true PE20000441A1 (es) | 2000-05-23 |
Family
ID=22178359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1999000356A PE20000441A1 (es) | 1998-04-29 | 1999-04-29 | Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado |
Country Status (42)
Country | Link |
---|---|
EP (1) | EP1076652B1 (es) |
JP (1) | JP4652569B2 (es) |
KR (1) | KR100668412B1 (es) |
CN (2) | CN1298396A (es) |
AP (1) | AP1252A (es) |
AR (1) | AR018201A1 (es) |
AT (1) | ATE295839T1 (es) |
AU (1) | AU759691C (es) |
BR (1) | BR9910025A (es) |
CA (1) | CA2330447C (es) |
CO (1) | CO5060467A1 (es) |
CZ (1) | CZ298230B6 (es) |
DE (1) | DE69925366T2 (es) |
DZ (1) | DZ2777A1 (es) |
EA (1) | EA002836B1 (es) |
EG (1) | EG24000A (es) |
ES (1) | ES2238825T3 (es) |
GT (1) | GT199900063A (es) |
HK (1) | HK1037180A1 (es) |
HN (1) | HN1999000057A (es) |
HU (1) | HU227569B1 (es) |
ID (1) | ID27198A (es) |
IL (1) | IL139172A0 (es) |
MA (1) | MA26624A1 (es) |
ME (1) | MEP42008A (es) |
MX (1) | MXPA00010610A (es) |
MY (1) | MY136033A (es) |
NO (1) | NO317301B1 (es) |
NZ (1) | NZ508154A (es) |
OA (1) | OA11769A (es) |
PA (1) | PA8471001A1 (es) |
PE (1) | PE20000441A1 (es) |
PL (1) | PL196940B1 (es) |
RS (1) | RS50081B (es) |
SA (1) | SA99200216B1 (es) |
TN (1) | TNSN99079A1 (es) |
TR (1) | TR200003166T2 (es) |
TW (1) | TWI248437B (es) |
UA (1) | UA60363C2 (es) |
UY (1) | UY26099A1 (es) |
WO (1) | WO1999055683A1 (es) |
ZA (1) | ZA992972B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
US7148231B2 (en) * | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
MXPA05012939A (es) | 2003-05-30 | 2006-05-17 | Astrazeneca Uk Ltd | Procedimiento. |
BRPI0411126A (pt) | 2003-06-10 | 2006-07-18 | Hoffmann La Roche | derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
CA2565721C (en) | 2004-05-06 | 2015-10-06 | Bioresponse, L.L.C. | Diindolymethane formulations for the treatment of leiomyomas |
ATE497762T1 (de) | 2004-12-30 | 2011-02-15 | Bioresponse Llc | Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus |
CA2659307A1 (en) | 2006-07-28 | 2008-01-31 | Synthon B.V. | Crystalline erlotinib |
WO2008057253A2 (en) | 2006-10-27 | 2008-05-15 | Bioresponse, L.L.C. | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
AU2008235274B2 (en) * | 2007-04-04 | 2013-04-18 | Cipla Limited | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
ES2492645T3 (es) | 2007-07-11 | 2014-09-10 | Hetero Drugs Limited | Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib |
WO2009024989A2 (en) | 2007-08-17 | 2009-02-26 | Hetero Drugs Limited | A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
KR101132937B1 (ko) * | 2008-10-01 | 2012-04-06 | 주식회사종근당 | N-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염 |
US8440823B2 (en) | 2009-03-26 | 2013-05-14 | Ranbaxy Laboratories Limited | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof |
WO2011068404A2 (en) | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation |
DE202010006543U1 (de) | 2010-05-07 | 2010-09-09 | Ratiopharm Gmbh | Erlotinibresinat |
HU230483B1 (hu) | 2011-10-10 | 2016-07-28 | Egis Gyógyszergyár Nyrt. | Erlotinib sók |
WO2014037961A1 (en) | 2012-09-04 | 2014-03-13 | Shilpa Medicare Limited | Crystalline erlotinib hydrochloride process |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
JP2994165B2 (ja) * | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
ES2332984T3 (es) * | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
-
1999
- 1999-04-08 JP JP2000545843A patent/JP4652569B2/ja not_active Expired - Lifetime
- 1999-04-08 RS YUP-661/00A patent/RS50081B/sr unknown
- 1999-04-08 CZ CZ20003974A patent/CZ298230B6/cs not_active IP Right Cessation
- 1999-04-08 MX MXPA00010610A patent/MXPA00010610A/es active IP Right Grant
- 1999-04-08 EP EP99909165A patent/EP1076652B1/en not_active Expired - Lifetime
- 1999-04-08 AT AT99909165T patent/ATE295839T1/de not_active IP Right Cessation
- 1999-04-08 OA OA1200000300A patent/OA11769A/en unknown
- 1999-04-08 HU HU0101818A patent/HU227569B1/hu unknown
- 1999-04-08 BR BR9910025-8A patent/BR9910025A/pt not_active Application Discontinuation
- 1999-04-08 ES ES99909165T patent/ES2238825T3/es not_active Expired - Lifetime
- 1999-04-08 CN CN99805497A patent/CN1298396A/zh active Pending
- 1999-04-08 NZ NZ508154A patent/NZ508154A/en not_active IP Right Cessation
- 1999-04-08 AU AU28509/99A patent/AU759691C/en not_active Expired
- 1999-04-08 PL PL343766A patent/PL196940B1/pl not_active IP Right Cessation
- 1999-04-08 KR KR1020007011998A patent/KR100668412B1/ko not_active IP Right Cessation
- 1999-04-08 CA CA002330447A patent/CA2330447C/en not_active Expired - Lifetime
- 1999-04-08 ID IDW20002186A patent/ID27198A/id unknown
- 1999-04-08 WO PCT/IB1999/000612 patent/WO1999055683A1/en active IP Right Grant
- 1999-04-08 TR TR2000/03166T patent/TR200003166T2/xx unknown
- 1999-04-08 EA EA200001112A patent/EA002836B1/ru not_active IP Right Cessation
- 1999-04-08 DE DE69925366T patent/DE69925366T2/de not_active Expired - Lifetime
- 1999-04-08 CN CNA2008100051101A patent/CN101219999A/zh active Pending
- 1999-04-08 ME MEP-420/08A patent/MEP42008A/xx unknown
- 1999-04-08 IL IL13917299A patent/IL139172A0/xx not_active IP Right Cessation
- 1999-04-23 TW TW088106555A patent/TWI248437B/zh not_active IP Right Cessation
- 1999-04-26 HN HN1999000057A patent/HN1999000057A/es unknown
- 1999-04-27 PA PA19998471001A patent/PA8471001A1/es unknown
- 1999-04-27 AR ARP990101942A patent/AR018201A1/es active IP Right Grant
- 1999-04-27 MY MYPI99001636A patent/MY136033A/en unknown
- 1999-04-28 ZA ZA9902972A patent/ZA992972B/xx unknown
- 1999-04-28 DZ DZ990077A patent/DZ2777A1/xx active
- 1999-04-28 TN TNTNSN99079A patent/TNSN99079A1/fr unknown
- 1999-04-28 MA MA25557A patent/MA26624A1/fr unknown
- 1999-04-29 EG EG48299A patent/EG24000A/xx active
- 1999-04-29 CO CO99026003A patent/CO5060467A1/es unknown
- 1999-04-29 GT GT199900063A patent/GT199900063A/es unknown
- 1999-04-29 AP APAP/P/1999/001523A patent/AP1252A/en active
- 1999-04-29 PE PE1999000356A patent/PE20000441A1/es not_active Application Discontinuation
- 1999-06-02 SA SA99200216A patent/SA99200216B1/ar unknown
- 1999-08-04 UA UA2000116681A patent/UA60363C2/uk unknown
-
2000
- 2000-04-05 UY UY26099A patent/UY26099A1/es not_active Application Discontinuation
- 2000-10-27 NO NO20005453A patent/NO317301B1/no not_active IP Right Cessation
-
2001
- 2001-08-17 HK HK01105821A patent/HK1037180A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20000441A1 (es) | Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado | |
PE20070496A1 (es) | Compuestos derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina | |
IS7319A (is) | Fjölgervingar klópídógrelvetnissúlfats | |
HUP0302345A2 (hu) | Új triazolo-pirimidin-vegyületek, ezek intermedierjei és eljárás az előállításukra | |
MY169791A (en) | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors | |
DE602004017196D1 (de) | Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren | |
IL174469A0 (en) | Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics | |
AR068086A2 (es) | Polimorfos del compuesto triazolo (4,5-d) pirimidina , una mezcla , proceso para su preparacion , composicion farmaceutica y uso de estos compuestos para la fabricacion de medicamentos | |
GEP20084528B (en) | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | |
CO5700731A2 (es) | Polimorfos cristalinos de un ligando receptor de cxc-quimiocina | |
MY142018A (en) | Thiophene derivatives as chk 1 inihibitors | |
YU34202A (sh) | Stabilni polimorf n-(3-etinilfenilamino)-6,7-bis(2- metoksietoksi)-4-kvinazolinamin hidrohlorida, postupci proizvodnje i njegova farmaceutska upotreba | |
ATE489354T1 (de) | Verfahren zur herstellung von metallorganischen gerüstmaterialien hauptgruppen metallionen enthaltend | |
SV2003001173A (es) | 1-alquil o 1-cicloalquil-triazolo [4,3-a] quinazolin-5- onas como inhibidoras de fosfodiesterasa | |
GB0222056D0 (en) | Process for the manufacture of organic compounds | |
WO2008020455A3 (en) | Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof | |
DOP2009000073A (es) | Inhibidores de cinasa que catalizan la transferencia de fosforilo y/o que enlazan nucleótidos atp/gtp. | |
PL371383A1 (en) | Process for the manufacture of organic compounds | |
BRPI0416690A (pt) | derivados de pirrol | |
CR7512A (es) | Procedimiento para preparar derivados de 6-alquiliden-penem | |
GB0210234D0 (en) | Process for the manufacture of organic compounds | |
IL162827A0 (en) | A process for producing phenserine and its analog | |
NZ589108A (en) | Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents | |
DE60313157D1 (de) | Ein verfahren zur herstellung von clopidogrel | |
IS8034A (is) | Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |